Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022

The global non-alcoholic fatty liver disease therapeutics market is predicted to reach a size of almost USD 2.8 billion by 2022 helped by the growing number of strategic alliances between vendors who offer fatty liver treatment. Wondering how to make the most of this booming non-alcoholic fatty liver disease therapeutics industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global non-alcoholic fatty liver disease therapeutics market. It also examines the competitive landscape and some key non-alcoholic fatty liver disease therapy companies that include ALLERGAN, GlaxoSmithKline, and Merck.

Get an impression below about how you can gain compelling insights from Technavio’s market research report? Check out the latest facts about the non-alcoholic fatty liver treatment industry

The global non-alcoholic fatty liver disease therapeutics market is expected to grow at a CAGR of over 16% during the forecast

Non-alcoholic fatty liver disease therapeutics industry growth is expected to accelerate massively over the next five years, driven by increasing prevalence of non-alcoholic fatty liver disease. The Americas will drive more than half of the growth for non-alcoholic fatty liver disease treatment companies, while EMEA and APAC are also predicted to contribute sizably to the incremental growth in the forecast period. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver dysfunction and a significant health problem across the globe. The major risk factors associated with NAFLD are obesity, gastric bypass surgery, hypertension, and type 2 diabetes. Technavio’s non-alcoholic fatty liver disease therapeutics industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Growing incidences of non-alcoholic fatty liver diseases is driving the market growth

The global non-alcoholic fatty liver disease therapeutics market is likely to be driven by growing cases of non-alcoholic fatty liver disease over the next few years. The prevalence of non-alcoholic fatty liver disease is increasing with the rise in obesity in industrialized societies which is expected to drive the growth for non-alcoholic fatty liver disease therapeutics. According to the NCBI, the global prevalence of obesity among males and females above 60 years of age was 13% and 19% respectively, and over 30% of the global adult population were found to be obese. The high incidence of these associated conditions is expected to boost the demand for fatty liver treatment across the period of forecast.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services. Start your 14-day FREE trial

ALLERGAN, GlaxoSmithKline, and Merck are among the leading non-alcoholic fatty liver disease therapeutics vendors

Most of the established non-alcoholic fatty liver disease therapeutics companies are focused on engaging in strategic alliances to strengthen their market position. Such acquisitions and alliances are expected to help the vendors extend their geographical reach and expand their product portfolio which is likely to contribute to the growth of the market. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• ALLERGAN
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch